Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma

Background Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have demonstrated promising efficacy in treating refractory or relapsed B-cell malignancies. Nonetheless, challenges such as antigen escape-mediated relapse and toxicities, including cytokine release syndrome (CRS) and neurot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of translational medicine Jg. 23; H. 1; S. 630 - 13
Hauptverfasser:	Wang, Hanyu, Wang, Gaoxiang, Li, Tongjuan, Zhang, Peiling, Mao, Zekai, Luo, Hui, Zhu, Xiaojian, Li, Dengju, Zhou, Jianfeng, Zhou, Xiaoxi, Huang, Liang
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 05.06.2025 BioMed Central Ltd BMC
Schlagworte:	Adult Aged Antigens, CD19 - immunology Antigens, CD19 - metabolism Biomedical and Life Sciences Biomedicine Cell Drug therapy Female Humans Immunotherapy, Adoptive - adverse effects Lymphoma, B-Cell - immunology Lymphoma, B-Cell - therapy Lymphoma, Non-Hodgkin - therapy Male Medicine/Public Health Middle Aged Neoplasm Recurrence, Local Non-Hodgkin's lymphomas Patient outcomes Physiological aspects Receptors, Chimeric Antigen - metabolism Recurrence Sialic Acid Binding Ig-like Lectin 2 - immunology Sialic Acid Binding Ig-like Lectin 2 - metabolism tissue and gene therapy Treatment Outcome China
ISSN:	1479-5876, 1479-5876
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!